trial summary · NCT07459634
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab
Trial record from the TrialBase DB dataset, status RECRUITING, condition Extensive-stage Small-cell Lung Cancer, sponsored by Jazz Pharmaceuticals. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Source record: https://clinicaltrials.gov/study/NCT07459634
Facts
| registry id | NCT07459634 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE2 |
| study type | INTERVENTIONAL |
| lead condition | Extensive-stage Small-cell Lung Cancer |
| sponsor | Jazz Pharmaceuticals |
| sponsor class | INDUSTRY |
| enrollment | 50 |
| start date | 2026-11-30 |
| primary completion | 2028-01-31 |
| completion | 2028-04-30 |
| results posted | not reported |
Conditions
- Extensive-stage Small-cell Lung Cancer
Interventions
- Lurbinectedin
- Durvalumab
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.